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Dbs is a Rho-specific guanine nucleotide exchange factor (RhoGEF) that exhibits transforming activity when
overexpressed in NIH 3T3 mouse fibroblasts. Like many RhoGEFs, the in vitro catalytic activity of Dbs is not
limited to a single substrate. It can catalyze the exchange of GDP for GTP on RhoA and Cdc42, both of which
are expressed in most cell types. This lack of substrate specificity, which is relatively common among members
of the RhoGEF family, complicates efforts to determine the molecular basis of their transforming activity. We
have recently determined crystal structures of several RhoGEFs bound to their cognate GTPases and have used
these complexes to predict structural determinants dictating the specificities of coupling between RhoGEFs
and GTPases. Guided by this information, we mutated Dbs to alter significantly its relative exchange activity
for RhoA versus Cdc42 and show that the transformation potential of Dbs correlates with exchange on RhoA
but not Cdc42. Supporting this conclusion, oncogenic Dbs activates endogenous RhoA but not endogenous
Cdc42 in NIH 3T3 cells. Similarly, a competitive inhibitor that blocks RhoA activation also blocks Dbs-
mediated transformation. In conclusion, this study highlights the usefulness of specificity mutants of RhoGEFs
as tools to genetically dissect the multiple signaling pathways potentially activated by overexpressed or
oncogenic RhoGEFs. These ideas are exemplified for Dbs, which is strongly implicated in the transformation
of NIH 3T3 cells via RhoA and not Cdc42.
Dbs is a Rho-specific guanine nucleotide exchange factor
(RhoGEF) that was identified in a screen for cDNAs whose
expression causes deregulated growth in NIH 3T3 mouse fi-
broblasts (37). The RhoGEFs are a large family of structurally
related proteins that share a common ability to catalyze the
exchange of GDP for GTP on members of the Rho family of
small GTPases (39). Like all GTP-binding proteins, Rho pro-
teins function as binary switches cycling between a biologically
inactive GDP-bound state and a biologically active GTP-bound
state. Conversion to the GDP-bound form is achieved through
intrinsic GTP hydrolysis, which can be further stimulated by
the actions of GTPase-activating proteins (18). Conversion to
the GTP-bound form is mediated by the actions of RhoGEFs,
which stimulate the dissociation of bound GDP, thus providing
an opportunity for GTP to bind (39). Since most Rho proteins
exhibit biological activity only when in the GTP-bound state,
RhoGEFs, such as Dbs, are primarily thought to be Rho acti-
vators.
The region of structural similarity that defines members of
the RhoGEF family consists of an approximately 200-amino-
acid Dbl homology (DH) domain that is always arranged in
tandem with a pleckstrin homology (PH) domain (39). The
DH domain contains most of the residues that are required for
RhoGEF catalytic activity, while the PH domain is generally
perceived to be noncatalytic in nature. Evidence from a variety
of sources suggests that the PH domain may perform several
functions in the context of a DH domain, which could include
structuring the DH domain (41), enhancing catalytic activity
(20), and promoting translocation to the plasma membrane
(38, 40). The sites within the plasma membrane that interact
with PH domains probably contain phosphoinositides, since
these are known ligands for the PH domains of a variety of
RhoGEFs (10, 20, 26, 34).
Although the RhoGEFs will utilize only members of the
Rho subfamily of small GTPases as substrates, they can exhibit
varying degrees of target specificity within the family. For ex-
ample, FGD1 and Cdc24 preferentially use Cdc42 as a sub-
strate (42, 43) and Trio and Tiam1 interact only with Rac1 (5,
13, 42, 43), while Lfc, Lsc, Lbc, and Net1 are able to exchange
only on RhoA (2, 8). In contrast, Dbs and Dbl can activate
both RhoA and Cdc42 (but not Rac1) (40, 44), while Vav1 and
Vav2 are able to activate RhoA, Rac1, and Cdc42 (1, 9, 33).
Whereas most of these specificity studies have been performed
in vitro with purified exchanger and substrate, it has not yet
been determined whether these RhoGEFs exhibit equivalent
specificities in vivo.
The deregulated expression of many members of the Rho-
GEF family, including Dbs, causes tumorigenic growth and
promotes the invasive potential of a variety of cell types (39).
This is particularly evident in NIH 3T3 mouse fibroblasts, in
which deregulated expression of RhoGEFs is often associated
with loss of contact inhibition, growth factor independence,
anchorage-independent growth, and tumorigenicity in nude
mice. Since guanine nucleotide exchange is the only activity
that has been demonstrated by many of the oncogenic Rho-
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GEFs and structure-function analyses of RhoGEFs generally
indicate a precise convergence between catalytic and trans-
forming activities (11, 40), it is assumed that Rho proteins
mediate RhoGEF transformation. Consistent with this, domi-
nant active mutants of several Rho family members (including
RhoA, Rac1, and Cdc42) have been shown previously to har-
bor substantial oncogenic potential when expressed in a variety
of cell types including NIH 3T3 cells (3, 17, 22–24, 36). How-
ever, activated derivatives of Rho GTPases often have much-
diminished transforming activity relative to the oncogenic
RhoGEFs, suggesting that the combined activities of multiple
GTPase substrates may be required to account for the full
transforming activity of a RhoGEF (19).
Like many members of the RhoGEF family, Dbs is trans-
forming when expressed in NIH 3T3 cells as measured by loss
of contact inhibition and growth factor independence (37, 40).
We have shown previously that Dbs can catalyze the exchange
of GDP for GTP on both Cdc42 and RhoA, but not Rac1, in
an in vitro system (40). Since activated derivatives of both
Cdc42 and RhoA are known to be transforming in NIH 3T3
cells, it is likely that one or both of these GTPases contribute
to Dbs transforming activity. However, the relative contribu-
tion of RhoA and Cdc42 to any cellular activities associated
with Dbs, including transformation, is unclear.
We have recently reported the structures of Dbs in complex
with Cdc42 (Dbs·Cdc42) (29) and RhoA (Dbs·RhoA) (35). In
this study, we have used these structures as a molecular frame-
work to begin to probe the rules governing DH domain spec-
ificity. Our analysis has allowed us to introduce point muta-
tions into the catalytic domain of Dbs that selectively narrow
its specificity of exchange. Expression of these mutants in NIH
3T3 cells reveals a precise correlation between Dbs transform-
ing activity and its ability to utilize RhoA (but not Cdc42) as a
substrate. This is consistent with observed increases in RhoA-
GTP but not Cdc42-GTP in Dbs-transformed cells and is fur-
ther confirmed by our ability to block Dbs transformation with
a competitive inhibitor of RhoA. These studies provide valu-
able insights into the rules governing substrate recognition by
RhoGEFs and important genetic tools that can be used in the
analysis of RhoGEF function.
MATERIALS AND METHODS
Molecular constructs. The pAX142 and pCTV3H mammalian expression vec-
tors have been described previously (37). pAX142-dbs-HA6, pCTV3H-dbs-HA6,
and pCTV3H-dbl-HA1 contain cDNAs that encode transforming derivatives of
the respective GEFs fused to a hemagglutinin (HA) epitope tag (40). A pET28a
(Novagen) bacterial expression construct that contains a carboxyl-terminal His6-
tagged, Dbs DH-PH domain (murine, residues 623 to 967) has been described
previously (40). cDNAs encoding human placental Cdc42 (residues 1 to 188;
C188S) and Rac1 (residues 1 to 189; C189S) were prepared by PCR and inserted
into pET21a (Novagen) for bacterial expression. A cDNA encoding human
RhoA (residues 1 to 190; C190S) was subcloned into the pProEX HT vector
(Life Technologies) for bacterial expression. Site-directed substitutions in the
Dbs DH-PH domain and Cdc42 constructs were prepared with the Quickchange
site-directed mutagenesis kit (Stratagene) per the manufacturer’s instructions.
Site-directed mutagenesis was also used to introduce equivalent point mutations
into the DH domain of the pAX142 and pCTV3H versions of Dbs-HA6. cDNA
sequences of all expression constructs were verified by automated sequencing.
pAX142-rac1, pAX142-rac1(61L), pAX142-rhoA, pAX142-rhoA(63L), pAX142-
cdc42, and pAX142-cdc42(12V) have been described previously (40, 45). GST-
PBD and GST-C21 contain the Rho binding domains from the Cdc42/Rac1
effector protein PAK3 and the RhoA effector protein Rhotekin, respectively (7,
28). pAX142-GST-C21 and pCTV3H-GST-C21 were made by transferring the
GST-C21 sequences (27, 28) into the pAX142 and pCTV3H expression vectors,
respectively. The (SREm)2-luc construct utilized in the transcriptional assays has
been described previously (36).
Cell culture, transfection, and transformation assays. NIH 3T3 cells were
maintained in Dulbecco’s modified Eagle’s medium (high glucose) supplemented
with 10% bovine calf serum (BCS; JRH, Lenexa, Kans.). Primary focus forma-
tion assays were performed in NIH 3T3 cells exactly as described previously (4).
Briefly, NIH 3T3 cells were transfected by calcium phosphate coprecipitation in
conjunction with a glycerol shock. Focus formation was scored at 14 days.
NIH 3T3 cells that stably express pCTV3H, pCTV3H-dbs-HA6, pCTV3H-dbl-
HA1, or the pCTV3H versions of the Dbs specificity mutants were generated by
calcium phosphate coprecipitation followed by selection for 6 days in growth
medium (10% BCS) supplemented with hygromycin B (200 g/ml). Cell lines
were then split 1:4, grown in the absence of selection until they reached 60%
confluence (approximately 4 days), and then frozen. All affinity precipitation and
transformation assays were performed with freshly thawed, single-passage cell
lines.
Secondary focus formation assays and assays for anchorage-independent
growth were performed with single-passage stable cell lines that had been main-
tained under subconfluent conditions. For secondary focus assays, 103 stably
selected cells were mixed with 106 untransfected NIH 3T3 cells and then plated
on 60-mm-diameter dishes. Foci were scored at 7 days. Anchorage-independent
growth was measured as described previously (4). Briefly, cell lines were seeded
at 104 cells per 60-mm-diameter dish in growth medium containing 0.3% agar
over a base layer of 0.6%. Colonies were counted after 21 days. All assays for
transformation were performed in triplicate.
Transient-expression reporter gene assays. For transient-expression reporter
assays, NIH 3T3 cells were transfected by calcium phosphate coprecipitation as
described previously (4). Cells were allowed to recover for 30 h and were then
starved in Dulbecco’s modified Eagle’s medium that was supplemented with
0.5% serum for 14 h before lysate preparation. Analysis of luciferase expression
was as described previously with enhanced chemiluminescent reagents and a
Monolight 3010 luminometer (Analytical Luminescence, San Diego, Calif.) (12,
25). -Galactosidase activity was determined with Lumi-Gal substrate (Lumigen,
Southfield, Mich.) according to the manufacturer’s instructions. All assays were
performed in triplicate.
Protein expression and purification. Protein expression in stably transfected
NIH 3T3 cells was determined by Western blot analysis as described previously
(38). Protein was visualized with enhanced chemiluminescence reagents (Amer-
sham Pharmacia, Piscataway, N.J.). Protein expression and purification of Dbs
DH-PH domain proteins were performed as described previously (29). Human
placental Cdc42 (residues 1 to 188; C188S) and Rac1 (residues 1 to 189; C189S)
were expressed and purified similarly as described previously (29). Human RhoA
(residues 1 to 190; C190S) was expressed in Escherichia coli strain BL21(DE3)
with a pProEX HT vector (Life Technologies) which encodes an amino-terminal
His6 tag. The His6 tag was removed by digestion with tobacco etch virus protease,
and RhoA was further purified as described previously (29).
Guanine nucleotide exchange assays. Fluorescence spectroscopic analysis of
N-methylanthraniloyl(mant)-GTP incorporation into bacterially purified Rho
GTPases was carried out with a Perkin-Elmer LS 50B spectrometer at 20°C.
Exchange reaction assay mixtures containing 20 mM Tris (pH 7.5), 50 mM NaCl,
10 mM MgCl2, 1 mM dithiothreitol, 50 g of bovine serum albumin/l, 10%
(vol/vol) glycerol, 400 nM mant-GTP (Biomol), and 2 M relevant GTPase were
prepared and allowed to equilibrate with continuous stirring. After equilibration,
Dbs DH-PH domain proteins were added at 100 nM, and the relative fluores-
cence (ex  360 nm, em  440 nm) was monitored.
Cdc42, Rac1, and RhoA activation assays. All affinity purification assays were
performed on cell lysates derived from single-passage stable cell lines that had
been established and maintained in subconfluent conditions. The p21 binding
domains of Pak3 (GST-PBD) (7) or Rhotekin (GST-C21) (28) were expressed as
glutathione S-transferase (GST) fusions in BL21(DE3) cells and immobilized by
binding to glutathione-coupled Sepharose 4B beads (Amersham Pharmacia).
The immobilized Rho binding domains were then used to precipitate activated
GTP-bound Rac1, Cdc42 (GST-PBD), or RhoA (GST-C21) from NIH 3T3 cell
lysates. Cells were washed in cold phosphate-buffered saline and then lysed in 50
mM Tris-HCl (pH 7.4)–2 mM MgCl2–100 mM NaCl–10% glycerol–1% NP-40–1
g of leupeptin/ml–1 g of pepstatin/ml–1 g of aprotinin/ml–1 g of phenyl-
methylsulfonyl fluoride/ml. Cell lysates were then cleared by centrifugation at
10,000  g for 10 min at 4°C. The expression of proteins was confirmed by
Western blotting prior to affinity purification. Lysates used for affinity purifica-
tion were normalized for endogenous Rho levels. Affinity purifications were
carried out at 4°C for 1 h, and the mixtures were washed three times in an excess
of lysis buffer and then analyzed by Western blotting. Cdc42, RhoA, and Rac1
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were detected by monoclonal antibodies (Cdc42 and RhoA [Santa Cruz Bio-
technology, Santa Cruz, Calif.] and Rac1 [BD Transduction Laboratories, Los
Angeles, Calif.]).
RESULTS
Dbs-HA6 activates RhoA, but not Cdc42, in stably trans-
formed NIH 3T3 cells. We have shown previously that Dbs is
highly transforming when stably expressed in NIH 3T3 cells as
measured by loss of contact inhibition and growth in low serum
(40). Since activated derivatives of both RhoA and Cdc42 are
also known to be transforming when stably expressed in NIH
3T3 cells, both are potential mediators of Dbs transforming
activity. To determine which (if either) of these two substrates
is contributing to Dbs-mediated transformation, we wished to
measure levels of endogenous RhoA-GTP, Cdc42-GTP, and
Rac1-GTP in NIH 3T3 cells that stably express an activated
derivative of Dbs. Dbs-HA6 is an oncogenic version of the Dbs
protein that includes intact DH and PH domains along with
some flanking sequences (40). Because Dbs and Dbl share
identical in vitro exchange profiles, we also assayed an onco-
genic derivative of Dbl (Dbl-HA1) for comparison (40). To
avoid the risk of characterizing clonal variants, four indepen-
dent matched pairs of stable cell lines were established for
vector and Dbs-HA6 (designated Dbs-HA6-S1, -S2, -S3, and
-S4), while an additional fifth matched pair was established for
Dbl-HA1. Surprisingly, all the cell lines that express either
Dbs-HA6 or Dbl-HA1 showed elevated levels of RhoA-GTP
relative to vector controls but not Cdc42-GTP or Rac1-GTP
(Fig. 1A and Table 1). To determine whether lack of Cdc42
and Rac1 activation could be attributed to saturation of the
pull-down assay, we serum starved the cells for 18 h prior to
lysate collection and then repeated the assays. Even though the
endogenous levels of Rac1-GTP and Cdc42-GTP were re-
duced in response to the serum deprivation, we were still
unable to observe any elevation in Rac1-GTP or Cdc42-GTP
levels in the Dbl-HA1- or Dbs-HA6-transformed cell lines
(Fig. 1A and Table 1). As an additional verification that our
assay was sufficiently sensitive to detect changes in the endog-
enous pool of activated Cdc42 and Rac1, we transiently trans-
fected NIH 3T3 cells with Cdc42(12V) (Fig. 1B) or Rac1(61L)
(Fig. 1C). Although the level of expression of both the
Cdc42(12V) and Rac1(61L) mutants was undetectably low in
whole-cell lysates (lower panels in Fig. 1B and C), we were still
able to affinity precipitate both and demonstrate their presence
in the Cdc42-GTP and Rac1-GTP pools (upper panels in Fig.
1B and C). Thus, the lack of Cdc42 and Rac1 activation in our
stable assays cannot be attributed to a lack of sensitivity of the
affinity precipitations.
To determine whether Dbs and Dbl transformation is asso-
ciated with a transient activation of Cdc42 or Rac1, affinity
precipitation assays were also performed on NIH 3T3 cells that
were transiently transfected with Dbl-HA1 or Dbs-HA6. Al-
though both proteins failed to generate any detectable in-
creases in Cdc42-GTP or Rac1-GTP levels when expressed
transiently in NIH 3T3 cells, we were unable to detect expres-
sion of the proteins in the whole-cell lysates (data not shown).
Thus, it may not be possible to achieve sufficiently high tran-
sient expression of Dbl-HA1 and Dbs-HA6 in NIH 3T3 cells to
have any measurable effects on Cdc42 or Rac1 GTP levels. To
summarize, although we cannot formally exclude the possibil-
ity that transient activation of Cdc42 or Rac1 may contribute to
the initiation of Dbs- and Dbl-mediated transformation, nei-
ther GTPase seems to make a contribution to the maintenance
of the transformed phenotype.
Altering substrate specificity of the Dbs DH domain. Al-
though we did not observe any increases in Cdc42-GTP in
Dbs-transformed NIH 3T3 cells, it is possible that Cdc42 is
cycling more rapidly in these cells and that this accelerated
cycling is not being reflected in the Cdc42-GTP steady-state
levels. Alternatively, Dbs transformation may be associated
with a transient activation of Cdc42 that we are unable to
measure with our affinity precipitations. To address these con-
cerns, it was necessary to develop an alternative and comple-
mentary approach to determine the relative contributions of
Cdc42 and RhoA to the transforming activity of Dbs. Towards
this end, we wished to introduce mutations into the Dbs DH
domain that would act to uncouple activation of RhoA and
Cdc42. Such mutants would be valuable genetic tools that
could be used to determine the relative contribution of each
GTPase to the various in vivo functions of Dbs, including
transformation. We have recently reported structures of sev-
eral RhoGEFs in complex with their cognate GTPases (29, 35,
41), and based on these analyses, we are able to test specific
predictions regarding the molecular bases for discrimination of
Rho GTPases by DH domains.
As proposed for Tiam1·Rac1 (41), the 4-5a region of the
Dbs DH domain likely recognizes a specificity patch on
-strands 1 to 3 of Rho GTPases (Thr 3, Ala 41, Thr 43, Thr
52, and Phe 56 in Cdc42) to discriminate between Rho GT-
Pases (Fig. 2A and B). Importantly, Trp 56 of Rac1, analogous
to Phe 56 in Cdc42 and Trp 58 in RhoA, has recently been
reported to be a primary determinant mediating DH domain
TABLE 1. Rho-GTP loading in NIH 3T3 cell lines that stably express Dbs-HA6 or Dbl-HA1a
Cell line RhoA
Rac1b Cdc42
10% BCS 0.5% BCS 10% BCS 0.5% BCS
Dbs-HA6-S1 5.1  0.8 1.1  0.1 1.1  0.1 1.0  0.1 0.9  0.1
Dbs-HA6-S2 8.2 1.1 0.9 1.3 0.8
Dbs-HA6-S3 3.8 1.0 1.3 1.2 1.2
Dbs-HA6-S4 5.6 1.2 1.1 1.2 1.3
Dbl-HA1 5.3  0.7 1.3  0.2 1.2  0.1 1.1  0.1 1.0  0.1
a Rho-GTP levels were determined by phosphorimager analysis and are expressed as fold activation relative to matched vector cell lines. For the Dbs-HA6-S1 and
Dbl-HA1 cell lines assays were repeated a minimum of four times and data are presented  standard deviations. For the remaining cell lines assays were performed
twice for each condition and a representative data set is shown.
b Rac1-GTP and Cdc42-GTP levels were determined under normal serum conditions (10% BCS) or after 18 h of serum starvation (0.5% BCS).
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specificity toward Rho GTPases (6, 15). For example, the
Rac1-to-Cdc42 alteration (W56F) abolishes Rac1 activation by
Tiam1 and allows activation by Intersectin, a Dbl family mem-
ber specific for Cdc42 (15). Similarly, the structure of
Dbs·Cdc42 highlights the insertion of Phe 56 of Cdc42 into a
cleft of Dbs formed by leucines 759 and 766 to generate fa-
vorable hydrophobic packing interactions that promote bind-
ing (Fig. 2A). Docking a model of Rac1 upon the Dbs DH
domain suggests that Rac1 residues Ser 41, Asn 43, and Asn 52
would likely be tolerated in a Dbs·Rac1 complex, although the
bulkier side chain of Trp 56 would sterically impinge upon
L766 of Dbs to hamper binding and exchange and may explain
why Dbs cannot support exchange upon Rac1 (data not
shown).
RhoA also possesses a tryptophan (Trp 58) equivalent to
position 56 of Rac1, raising the question of how Dbs catalyzes
nucleotide exchange on RhoA but not Rac1. Within the struc-
ture of Dbs·RhoA (Fig. 2C), Lys 758 of Dbs is located between
Asp 45 and Glu 54 of RhoA (Asn 43 and Asn 52 in Rac1 and
Thr 43 and Thr 52 in Cdc42) to form significant electrostatic
interactions not possible with either Rac1 or Cdc42. In addi-
tion, Leu 759 of Dbs is located between Val 43 and Ala 56 in
RhoA (Ser 41 and Gly 54 in Rac1 and Ala 41 and Gly 54 in
Cdc42), resulting in a more extensive hydrophobic interface
than possible with Rac1 or Cdc42. The additional binding
energy afforded by these sets of interactions could compensate
for a seemingly poor fit of Trp 58 of RhoA into the Dbs DH
domain cleft, allowing Dbs binding and exchange of RhoA.
Based on our structures of Dbs·Cdc42 and Dbs·RhoA, we
have mutated Dbs to alter its specificity for Cdc42 relative to
RhoA (Fig. 3 and Table 2). Mutations were placed primarily at
positions 759 and 766 of Dbs (Fig. 2) to remodel the binding
cleft normally sequestering Phe 56 of Cdc42 or Trp 58 of
RhoA. Substitution of either methionine or isoleucine for Leu
759 of Dbs indiscriminately crippled nucleotide exchange on
both Cdc42 and RhoA. However, substitution of methionine or
isoleucine for Leu 766 (analogous to Ile 1187 in Tiam1) con-
ferred on Dbs an enhanced ability to exchange RhoA while
showing wild-type ability (L766I) or a diminished ability
(L766M) to exchange Cdc42. Furthermore, both mutations
allowed Dbs to support exchange upon Rac1, with Dbs (L766I)
exhibiting robust activity toward Rac1 (Fig. 3C). Therefore,
L766M and L766I in Dbs likely enlarge the binding cleft to
accommodate Trp 56 of Rac1 and Trp 58 of RhoA. In support
of the idea that Dbs (L766I) relieves steric crowding within the
binding pocket formed by leucines 759 and 766, Cdc42(F56W)
is a poor substrate for wild-type Dbs but an exceedingly robust
substrate for Dbs(L766I) (Fig. 3J). We caution, however, that
the equivalent of position 56 cannot be the sole determinant of
specificity utilized by DH domains, since Cdc42(F56W) is not
exchanged by the DH-PH domains of Tiam1 (data not shown
and reference 15).
FIG. 1. Elevated levels of RhoA-GTP in NIH 3T3 cells stably transfected with a transforming derivative of Dbs. (A) Lysates were collected
from NIH 3T3 cell lines that stably express either Dbs-HA6, Dbl-HA1, or the cognate pAX142 vector. Lysates were examined by Western blotting
for expression of RhoA (Total RhoA), Cdc42 (Total Cdc42), Rac1 (Total Rac1), and the transforming HA-tagged derivatives (anti-HA). Lysates
were then split into three parts, each of which was normalized for expression of either RhoA, Rac1, or Cdc42. Each lysate was then subjected to
affinity purification with immobilized GST-PBD (Rac1 and Cdc42) or GST-C21 (RhoA). GTP-bound Cdc42 (GTP-Cdc42) and Rac1 (GTP-Rac1)
that were precipitated with GST-PBD or GTP-bound RhoA (GTP-RhoA) that was precipitated with GST-C21 were visualized by Western blotting.
For the Rac1 and Cdc42 assays affinity purifications were performed on cells that had been maintained under normal serum levels (10%) or serum
starved (0.5%) for 18 h prior to lysate collection. (B and C) NIH 3T3 cells were transiently transfected with plasmids that encoded activated
derivatives of Cdc42 (B) or Rac1 (C). Lysates were collected at 48 h, and affinity purifications were performed as described above. All experiments
were performed a minimum of three times, and data shown constitute a representative data set.
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Substitution of glutamate (Q752E) for Gln 752 within the
Dbs DH domain was hypothesized to bolster Dbs activity to-
ward RhoA by encouraging electrostatic interactions with Arg
5 of RhoA (Fig. 2C). Indeed, a small increase in RhoA acti-
vation by Dbs (Q752E) is observed along with reduced ex-
change of Cdc42, indicating that a glutamate at position 752
confers increased RhoA specificity on Dbs (Fig. 3D to F).
The functional effects of double mutations within a protein
are, in general, equivalent to the sums of the effects of the
constituent single substitutions (30). To generate mutants that
further impair the ability of Dbs to activate Cdc42, we sepa-
rately combined the single substitutions Q752E, L759M, and
L759I with L766M and assessed their effects upon Dbs-cata-
lyzed exchange for Cdc42, RhoA, and Rac1 (Fig. 3G to I;
Table 2). All three doubly substituted Dbs proteins showed
further decreases in their ability to activate Cdc42, with Dbs
(L759I/L766M) being completely inactive toward Cdc42. Dbs
(L759M/L766M) and Dbs (Q752E/L766M) retained wild-type
and greater-than-wild-type activity toward RhoA, respectively,
while Dbs (L759I/L766M) showed a marked decrease in the
ability to activate RhoA. None of the three doubly substituted
Dbs proteins exhibited significant activity toward Rac1.
FIG. 2. Specificity determination within the structures of Dbs·Cdc42 and Dbs·RhoA. (A) A ribbon diagram of the Dbs DH domain (yellow)
bound to a GTPase (green) highlighting the specificity patch on -strands 1 to 3 (magenta) of Rho GTPases and the complementary interface on
DH domains (4-5a region; cyan). (B) Close-up of the interactions within the specificity patch for Dbs·Cdc42 (Protein Data Bank accession no.
1KZ7) highlighting the hydrophobic pocket formed by leucines 759 and 766 of Dbs and encompassing Phe 56 of Cdc42. (C) Within the equivalent
region of Dbs·RhoA (Protein Data Bank accession no. 1LB1), the hydrophobic pocket adjusts to accommodate Trp 58 of RhoA. Val 43 and Ala
56 of RhoA also participate favorably with the hydrophobic pocket. Also shown is the electrostatic interaction of Lys 758 of Dbs with Asp 45 and
Glu 54 of RhoA.
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Determination of substrate usage by Dbs specificity mutants
in NIH 3T3 cells. Having generated Dbs mutants that are
selectively impaired in their ability to catalyze exchange on
Cdc42, we wished to use these mutants to determine the con-
tribution of Cdc42 to Dbs transformation in NIH 3T3 cells. For
this analysis, a subset of six Dbs mutants were selected to
reflect the various ratios of catalyzed activation possible be-
tween Cdc42 and RhoA: Q752E/L766M, L759M/L766M, and
L766M engender Dbs with elevated exchange on RhoA while
significantly reducing exchange on Cdc42; L766I increases
RhoA exchange while not perturbing exchange on Cdc42; and
L759I and L759I/L766M significantly reduce exchange on both
GTPases. Initially we wanted to determine whether the in vitro
exchange activity of our panel members could be recapitulated
in NIH 3T3 cells. Towards this end, all of the mutations were
placed into the background of Dbs-HA6 and stable NIH 3T3
cell lines were constructed that expressed each of the mutants
(Fig. 4). To avoid the risk of analyzing a clonal variant, two
independent polyclonal cell lines were established for each cell
line. Although Fig. 4 shows the results of a single matched set
of cell lines, we observed identical results with the second
matched set (data not shown). Expression of all mutants was
verified by Western blotting with an anti-HA antibody and was
found to be equivalent for all members of the panel (Fig. 4,
bottom panel). Lysates were then collected and subjected to
affinity precipitation to measure levels of activated RhoA and
Cdc42 (Fig. 4). The levels of RhoA-GTP that we observed
were in general accordance with what we had observed in our
in vitro assays. The two cells lines that express mutants that are
defective in RhoA exchange (L759I and L759I/L766M) con-
FIG. 3. Mutations within the Dbs DH domain that alter specificity toward Rho GTPases. Substitutions within the DH domain of Dbs
differentially affect its ability to activate Cdc42 (A, D, and G), RhoA (B, E, and H), and Rac1 (C, F, and I). L766I within the DH domain of Dbs
effectively compensates for the substitutions for F56W within Cdc42 (J). For each reaction, 2 M GTPase was preincubated with 400 nM
mant-GDP for 300 s prior to the addition of catalytic amounts (100 M) of wild-type (wt; gray traces) or mutant Dbs as indicated. Spontaneous
exchange rates are also shown (black traces) and indicated with the names of the relevant GTPases. RhoGEF addition is defined as the
experimental start (time zero).
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tained very low levels of RhoA-GTP compared to Dbs-HA6,
while the remainder of the cell lines contained RhoA-GTP
levels that were equivalent to that of the Dbs-HA6 cell line.
The enhanced RhoA exchange that we observed in vitro with
the L766I, L766M, and Q752E/L766M mutants was not re-
flected in measurable increases in steady-state levels of RhoA-
GTP in vivo. This may reflect an inability to detect the modest
increases of steady-state levels of RhoA-GTP that are associ-
ated with these mutants (Fig. 3B and H). As expected, no
changes were detected in endogenous Cdc42-GTP levels for
any of the mutants, which is consistent with our previous ob-
servation that Dbs-HA6 does not activate Cdc42 in stable NIH
3T3 cell lines. This also suggests that the decreased levels of
RhoA-GTP observed in the L759I and L759I/L766M cell lines
cannot be attributed to a nonspecific overall reduction in Rho-
GTP levels in these cell lines. Since the L766I mutant had
acquired the ability to exchange on Rac1 in vitro, we also
examined this cell line for Rac1-GTP levels and observed no
difference relative to the wild-type control (data not shown).
To address the possibility that Cdc42-GTP and Rac1-GTP
levels are saturated under 10% serum conditions, assays were
repeated following serum starvation (0.5% BCS) for 18 h with
no significant differences observed (data not shown).
Dbs transforming activity in NIH 3T3 cells correlates with
endogenous levels of RhoA-GTP. The altered specificity of the
Dbs mutants for their substrates, both in vitro and in vivo,
suggested that they may be useful tools to examine the relative
contributions of RhoA and Cdc42 to Dbs transforming activity.
It has been shown previously that Dbs has transforming activity
in NIH 3T3 cells as measured by primary focus formation
assays (37, 40). To determine whether this parameter of trans-
formation was impaired in our mutants, a primary focus for-
mation assay was performed with the complete panel (Fig. 5A).
Focus formation is observed in NIH 3T3 cells at approximately
10 to 14 days posttransfection, which is the point at which we
are able to detect elevated RhoA-GTP in our stable cell lines.
An examination of the transforming potential of the three
Cdc42-defective mutants (Q752E/L766M, L759M/L766M, and
L766M) indicates that there is no meaningful relationship be-
tween Cdc42 activation and transforming activity. Whereas all
are substantially impaired in Cdc42 exchange, all retain wild-
type levels of transforming activity. In contrast, there appears
to be a more precise correlation between transformation and
RhoA activation. The L766I mutant is selectively enhanced in
RhoA exchange activity and exhibits increased transformation,
while the two mutants that are impaired in RhoA exchange
(L759I and L759I/L766M) are impaired in transformation.
Our observation that the L766I mutant exhibits increased
transforming activity in the absence of any discernible increase
in steady-state RhoA-GTP levels may reflect increased cycling
associated with endogenous RhoA. Alternatively, it may reflect
the ability of this mutant to exchange on Rac1, although we
also did not observe any increase in steady-state levels of Rac1-
GTP in this cell line. To summarize, Dbs transforming activity
FIG. 4. Substrate specificities of Dbs mutants are confirmed in
vivo. GTP-RhoA and GTP-Cdc42 levels were measured in NIH 3T3
cells stably transfected with Dbs mutants. Lysates were collected from
NIH 3T3 cell lines that stably express either Dbs-HA6, Dbs-HA6
mutants, or the cognate pAX142 vector. Lysates were examined by
Western blotting for expression of RhoA (Total RhoA), Cdc42 (Total
Cdc42), and the HA-tagged Dbs mutants (anti-HA). Lysates were then
split into two parts, each of which was normalized for expression of
either RhoA or Cdc42. Each lysate was then subjected to affinity
purification with immobilized GST-PAK (Cdc42) or GST-C21
(RhoA). GTP-bound Cdc42 (GTP-Cdc42) that was precipitated with
GST-PAK or GTP-bound RhoA (GTP-RhoA) that was precipitated
with GST-C21 were visualized by Western blotting. All experiments
were performed a minimum of three times on two independent sets of
polyclonal cell lines. Data shown constitute a representative data set.
TABLE 2. Initial rates of guanine nucleotide exchange reactions catalyzed by wild-type and mutant Dbs proteins on Cdc42, RhoA, and Rac1a
Protein
designation
Cdc42 RhoA Rac1 Cdc42 (F56W)
(RF s	1) Foldactivation (RF s
	1) Foldactivation (RF s
	1) Foldactivation (RF s
	1) Foldactivation
WT 3.95 49 1.44 48 0.02 1 0.65 8
L759M 1.94 24 0.44 15 0.02 1
L759I 0.24 3 0.17 6 0.02 1
L766M 0.50 6 3.02 101 0.08 4
L766I 4.39 55 8.00 267 1.13 57 6.45 81
Q752E 2.05 26 1.62 54 0.02 1
L759M/L766M 0.25 3 1.35 45 0.05 3
L759I/L766M 0.07 1 0.38 13 0.02 1
Q752E/L766M 0.31 4 2.61 87 0.08 4
a The initial rates of guanine nucleotide exchange for 2 M wild-type (WT) GTPase stimulated by 0.1 M concentrations of various Dbs proteins were determined
by linear regression analysis of approximately the first 60 s of the Dbs-catalyzed reactions from Fig. 3. The fold activation for each Dbs protein reflects the ratio of the
initial exchange rate measured for the GEF-containing reaction to the intrinsic rate of exchange for each GTPase. Intrinsic value of exchange: Cdc42, 0.08; RhoA, 0.03;
Rac1, 0.02; and Cdc42 (F56W), 0.08 relative fluorescence (RF) units per second.
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in NIH 3T3 cells correlates more closely with its ability to
activate RhoA than with its ability to activate Cdc42.
It has been argued previously for the Dbl protein that dif-
ferent parameters of transformation in NIH 3T3 cells are me-
diated by different Rho GTPase targets (19). For example, it
has been suggested elsewhere that loss of contact inhibition
(which is measured by primary and secondary focus formation
assays) may be mediated by RhoA, while anchorage-indepen-
dent growth (as measured by growth in soft agar) may be
mediated by Cdc42 (19). To determine whether this also ap-
plies to Dbs, we performed secondary focus formation assays
(Fig. 5B) and soft agar assays (Fig. 5C) with the NIH 3T3 cell
lines that stably express the Dbs DH domain mutants. In both
assays the transformation profile of the panel was similar to
what we observed with the primary focus formation assay. This
strongly suggests that the loss of contact inhibition and the
anchorage-independent growth associated with Dbs are unre-
lated to its ability to exchange on Cdc42 but rather correlate
with its activity toward RhoA. In contrast with the primary
focus assay, the L759I/L766M mutant exhibited some trans-
forming activity in the secondary focus and soft agar assays.
This is consistent with the modest RhoA activation that is
observed with this mutant in the in vitro exchange assays (Fig.
3H) and may reflect greater sensitivity associated with these
two transformation assays. Surprisingly, we did not observe any
significant increases in transforming activity (relative to the
Dbs-HA6 control) in the soft agar assay with any of the mu-
tants. This may indicate that there is an upper threshold of
activity that can be achieved in this assay with activated en-
dogenous RhoA. Collectively, these results further support the
hypothesis that Dbs transformation in NIH 3T3 cells is unre-
lated to Cdc42 activation and further implicate RhoA as the
more meaningful in vivo substrate in this cell type.
A competitive inhibitor of RhoA blocks Dbs transformation.
Although we have established a good correlation between
RhoA activation and Dbs-mediated transformation of NIH
3T3 cells, we wanted to make a more direct demonstration that
RhoA activation is necessary for the transformed phenotype.
Toward this end, we wished to determine whether a competi-
tive inhibitor of RhoA function could block Dbs transforma-
tion. Although dominant-inhibitory mutants of RhoA have
been described which could be used for such an analysis, such
mutants have relatively low utility since they can bind to mul-
tiple RhoGEFs in any given cell type, thus potentially blocking
additional signaling pathways (21, 22). In contrast, the GST-
C21 fusion protein that we utilize for our GST pull-down
assays interacts specifically with the GTP-bound forms of
RhoA and RhoC (32). Since RhoC is not expressed in NIH
3T3 cells (unpublished observations), this reagent should func-
tion as a highly specific inhibitor of RhoA in this cell type. This
high degree of target specificity selectively associated with Rho
binding domains has been exploited previously to generate
inhibitors of Rho proteins that have a much higher degree of
target specificity (21, 22). With this strategy in mind we trans-
ferred GST-C21 into the pAX142 mammalian expression vec-
tor and confirmed its stable expression by transient transfec-
tion and Western blotting in COS-7 cells (Fig. 6A). To confirm
that GST-C21 can block RhoA-mediated signaling events in
NIH 3T3 cells, we performed a transient reporter assay with
the (SREm)2-luc reporter and either RhoA(63L),
Cdc42(12V), or Dbs-HA6 in the presence or absence of the
inhibitor (Fig. 6B). RhoA(63L) is a GTPase-defective, consti-
tutively activated derivative of RhoA that should form nonpro-
ductive interactions with the GST-C21 inhibitor. Cdc42(12V)
is a constitutively activated derivative of Cdc42 that should not
interact with the inhibitor and is included as a control for
specificity. As predicted, reporter activation by RhoA(63L)
was substantially reduced in the presence of the inhibitor
(
60%) while activation by Cdc42(12V) was unaffected. Acti-
vation of the reporter by Dbs-HA6 was also substantially im-
paired in the presence of the inhibitor (
80%), suggesting that
Dbs activation of the (SREm)2-luc reporter is occurring in a
RhoA-dependent manner. We then determined whether the
inhibitor could block transformation by Dbs-HA6. Dbs-HA6
exhibited substantially reduced transforming activity (
60%)
in the presence of the inhibitor in an NIH 3T3 cell primary
focus formation assay (Fig. 6C). This reduction could not be
attributed to nonspecific growth inhibition, since the inhibitor,
when expressed alone, did not exhibit any growth inhibition
relative to vector controls (Fig. 6D). These observations sup-
port the model that the activated RhoA that we are able to
detect in stably transfected NIH 3T3 cells is contributing to
Dbs-HA6 transforming activity.
FIG. 5. Dbs transforming activity correlates with in vivo activation of RhoA. The transforming activity of the Dbs specificity mutants was
compared in primary focus assays (A), secondary focus assays (B), and soft agar assays (C). Assays were performed as described in Materials and
Methods. For primary focus assays NIH 3T3 cells were transfected with 3 g of plasmid DNA for each condition. Data shown are representative
of three assays performed on triplicate plates.
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DISCUSSION
Expression of RhoGEFs in many cell types is often associ-
ated with multiple cellular events including transcriptional reg-
ulation, entry into the cell cycle, cytoskeletal rearrangements,
and oncogenic transformation. Historically, however, the rele-
vant GTPase substrates that mediate these events have been
difficult to identify. This difficulty can be generally attributed to
a lack of substrate specificity in vitro, coupled with a lack of
information about substrate utilization in vivo. Although re-
cently described assays which allow for accurate measurements
of Rho-GTP levels in cell lysates have been extremely helpful
in addressing the latter deficiency (27, 28), the promiscuous
targeting of GTPases by RhoGEFs remains problematic for
their analysis. In this study we have described a genetic ap-
proach that could be used to determine the relative contribu-
tions of GTPase substrates to the various cellular events that
are regulated by a single RhoGEF. Using the structures of
several RhoGEF·GTPases as a molecular framework, we have
been able to accurately predict amino acid substitutions that
uncouple the specificity of Dbs for its two in vitro targets,
RhoA and Cdc42. In our first application of this approach, we
have used these mutations to identify RhoA, but not Cdc42, as
an important mediator of Dbs transformation in NIH 3T3
cells. As we refine our understanding of the structural deter-
minants necessary to dictate productive coupling between
RhoGEFs and GTPases (35), we anticipate being able to more
fully dissect and understand the myriad biological outputs ini-
tiated by RhoGEFs operating on the large family of Rho GT-
Pases.
Since detailed structure-function analyses of Dbs have re-
vealed a precise convergence between its catalytic and trans-
forming activities (37, 40), it is presumed to cause deregulated
growth in NIH 3T3 cells through the aberrant stimulation of
Rho GTPase substrates. Since constitutively activated mutants
of RhoA and Cdc42 also exhibit transforming potential when
expressed in NIH 3T3 cells (22, 24, 40), they would both ap-
pear to be attractive candidates for mediators of Dbs transfor-
mation. However, despite the fact that chronic activation of
Cdc42 is associated with deregulated growth in NIH 3T3 cells,
we and others have made observations that suggest that Rho-
GEF-mediated transformation of NIH 3T3 cells can occur in a
Cdc42-independent manner. For example, several RhoGEFs
have been identified which exhibit potent transforming activity
in NIH 3T3 cells without exhibiting any measurable exchange
activity for Cdc42 in vitro (i.e., Lfc, Lsc, and Net1) (2, 8). In
addition, although many RhoGEFs (including Dbs) have been
isolated based on their activity in an NIH 3T3 cell primary
focus formation assay, Cdc42 does not exhibit this particular
parameter of transformation. This suggests that Cdc42 activa-
tion alone cannot account for the full transforming activity
associated with many RhoGEFs in NIH 3T3 cells. Our present
observation that a highly transforming derivative of Dbs does
not influence steady-state levels of Cdc42-GTP in stably trans-
fected NIH 3T3 cells further supports the contention that
Cdc42 does not contribute to the transforming activity of this
GEF. Although it is possible that Cdc42 activation may be
required for the initiation but not the maintenance of trans-
formation, our observation that Dbs specificity mutants which
FIG. 6. Suppression of Dbs-mediated transformation by a genetic
inhibitor of RhoA function. (A) Expression of GST-C21 in transiently
transfected COS-7 cells was determined with an anti-GST mouse
monoclonal antibody (SC138; Santa Cruz). (B) GST-C21 blocks acti-
vation of serum response factor by RhoA. NIH 3T3 cells were cotrans-
fected with 3 g of either pAX142 (vector), pAX142-rhoA(63L),
pAX142-cdc42(12V), or pAX142-dbs-HA6 and 3 g of pAX142-GST-
RBD, along with 2.5 g of (SREm)2-luc, and 500 ng of pCMVnlac as
an internal control for transfection efficiency and/or growth inhibition.
Luciferase and -galactosidase levels were measured and expressed as
fold activation relative to the level of activation seen with empty vector
control. Luciferase activity was then standardized relative to -galac-
tosidase activity. Data shown are representative of three independent
experiments performed on triplicate plates. Error bars indicate stan-
dard deviations. (C) GST-RBD blocks focus formation by Dbs-HA6.
NIH 3T3 cells were cotransfected with 3 g of pAX142-dbs-HA6 and
3 g of either pAX142 or pAX142-GST-RBD. Foci were counted at 14
days. The data presented are representative of three independent
experiments performed on triplicate plates. Error bars indicate stan-
dard deviations. (D) Clonogenic analyses showed that expression of
the GST-C21 plasmid did not cause nonspecific inhibition of cell
growth. NIH 3T3 cells were transfected with 3 g of pCTV3H-GST-
C21 or pCTV3H (vector) by calcium phosphate precipitation. At 24 h
posttransfection, cells were split 1:4 and selected for 10 days in hygro-
mycin B (200 g/ml). Plates were then stained, and cell clones were
counted.
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lack any appreciable Cdc42 exchange activity can retain full
transforming activity argues against such a possibility.
What then is the in vivo target for Dbs? Since RhoA is the
only GTPase that has been shown elsewhere to be capable of
inducing the formation of foci in an NIH 3T3 primary focus
formation assay (16), and RhoA is an in vitro substrate for
Dbs, it is a strong candidate for such a target. In this study we
observed elevated levels of RhoA-GTP in Dbs-transformed
NIH 3T3 cells. Similarly, Dbs mutants that were impaired in
RhoA exchange were consistently impaired in their transform-
ing activity. Importantly, a mutant that is selectively enhanced
in its RhoA activity exhibited enhanced transformation in both
primary and secondary focus formation assays. Finally, a com-
petitive inhibitor that targets RhoA in NIH 3T3 cells can
effectively block Dbs transforming activity.
It has been suggested previously that Dbl transformation of
NIH 3T3 cells may be accounted for by the simultaneous
activation of RhoA, Rac1, and Cdc42 and that each GTPase
may regulate a particular aspect of Dbl transformation (19).
Since activated RhoA can cause loss of contact inhibition in
NIH 3T3 cells, as measured by focus formation assays, while
activated Cdc42 can regulate changes in anchorage-indepen-
dent growth, as measured by growth in soft agar, both may
cooperate to account for the Dbs-transformed phenotype.
However, NIH 3T3 cells that stably express Dbs exhibit both
anchorage-independent growth and loss of contact inhibition,
even though they do not contain elevated levels of Cdc42, and
Dbs specificity mutants that are deficient in Cdc42 exchange
are not deficient in either of these two parameters of transfor-
mation. Thus, although it is formally possible that additional
GTPases may contribute to Dbs transformation in NIH 3T3
cells, it seems unlikely that Cdc42 is making a contribution.
These results are consistent with a recent demonstration that
RhoA is downregulated in NIH 3T3 cells that stably express
either activated Rac1 or Cdc42, suggesting that the simulta-
neous activation of RhoA with either Rac1 or Cdc42 in NIH
3T3 cells may not be achievable (31).
Although the bulk of our evidence at present implicates only
RhoA as a mediator of Dbs transformation, we cannot exclude
the possibility that other GTPases (other than Rac1 or Cdc42)
may also make contributions. Dbs can activate transcriptional
reporters in COS-7 cells in the absence of any detectable in-
fluence on RhoA-GTP and Cdc42-GTP levels, suggesting that
it is capable of forming productive interactions with additional
GTPases (unpublished observations). One additional GTPase
that may contribute to Dbs transformation is RhoC. RhoC is
highly related to RhoA structurally and will also form nonpro-
ductive complexes with the GST-Rhotekin inhibitor. However,
Ost, the rat ortholog of Dbs, is unable to catalyze exchange on
RhoC in vitro (14), and we are unable to detect expression of
RhoC in NIH 3T3 cells (unpublished observations). Thus, at
this time, we have no evidence that any GTPase other than
RhoA is contributing to NIH 3T3 transformation by Dbs.
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